Search results
After a decade, CRISPR gene editing is a 'revolution in progress.' What does the future hold?
USA TODAY via Yahoo News· 1 year agoMedical innovations typically take 17 years from the time a lightbulb goes off in a scientist's head...
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Investor's Business Daily· 2 years agoA cure for genetic diseases has been little more than a whisper — until now. Thanks to the work of...
The UK becomes the first country to approve CRISPR treatment
Popular Science via Yahoo News· 6 months agoA researcher handles a petri dish while observing a CRISPR/Cas9 process through a stereomicroscope....
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
InvestorPlace via Yahoo Finance· 1 year agoThe 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work...
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Drops
Investor's Business Daily· 2 years agoThe Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday,...
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
Investor's Business Daily· 8 months agoCrispr Therapeutics is facing its make-or-break moment as experts point to a pivotal decision in...
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2...
Business Insider via Yahoo News· 6 months agoThe FDA approved the first gene therapy for sickle cell anemia.Meletios Verras/ iStock The FDA...
Editas cashes in on CRISPR patent with Vertex deal
BioPharma Dive via Yahoo Finance· 5 months agoDive Brief: Days after winning U.S. approval of the first CRISPR gene-editing medicine, Vertex Pharmaceuticals is clearing up potential intellectual...
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
Investor's Business Daily· 7 months agoThe Food and Drug Administration gave Intellia Therapeutics the go-ahead to begin a pivotal study of...
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
Zacks via Yahoo Finance· 2 years agoEditas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10,...